Radium-223 dichloride (Indications)
Metastatic Castration-Resistant Prostate Cancer (mCRPC): Xofigo is indicated for the treatment of patients with mCRPC that has spread to bones but not to other organs. It is used in patients who are symptomatic and have received other therapies
such as hormonal treatment or chemotherapy.